SINGAPORE (Feb 28): Singapore eDevelopment (SeD) announced Wednesday that its biomedical subsidiary, Global BioLife Inc., has completed the Zaire Ebola virus research portion for the study of a new anti-viral drug called LB2.

With fatality rates of up to 90%, Ebola is a severe viral disease transmitted from wild animals to human beings through physical contact, then spreads through human to human contact. It is considered one of the most virulent infections known.

According to SeD, the LB2 drug displayed efficacy at a much lower dose than the only widely used therapeutic agent for Ebola infection, T-705 (Favipiravir).

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
Related Stories

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook